Slide 1: Q3 2022 webcast
1 Q3 2022 webcast CEO Pär Fors CFO Pernille Fabricius November 2, 2022 1
Slide 2: Agenda
Agenda • Q3 highlights • Strategic update • Business Unit performance • Group financials • 2022 outlook • Q&A Disclaimer This presentation contains forward-looking statements including projections on future financial results. Statements regarding the future are subject to risks and uncertainties tha
Slide 3: Q3 highlights
Q3 highlights • Continued execution on carveout of Revenue and operating margin infrastructure business 1000 5.1% 4,1 10 2.9% -1.3% 500 0 • Global delivery capabilities being 698 738 701 723 -1.5% 738 consolidated in the Philippines 0 -10 Q3-21 Q4-21 Q1-22 Q2-22 Q3-22 Revenue (DKKm) Operating profit
Slide 4: Strategic update
Strategic update TRANSFORMATION PROFITABILITY STRATEGY Specialized IT services provider Continued pickup in SBTi commitment in Q3 with two strongly positioned Q3 after adjustments Carsten Ringius joins as CFO business units and improved utilization Pernille Fabricius drives transformation NEXT STEPS
Slide 5: Life Sciences Solutions (LSS)
Life Sciences Solutions (LSS) • 20% revenue growth driven by Revenue and gross margin acquisitions and international sales 300 24.0% 24.9% 19.1% 21.4% 30 14.0% 200 10 • Good pickup in earnings due to 100 191 199 198 222 229 improved capacity utilization 0 -10 Q3-21 Q4-21 Q1-22 Q2-22 Q3-22 Revenue (D
Slide 6: Cloud & Digital Solutions (CDS)
Cloud & Digital Solutions (CDS) • Moderate revenue growth driven by Revenue and gross margin sales to Life Sciences customers 300 20.3% 30 12.4% 18.3% 12.6% 9.1% 200 10 • Stable sales to other customer 100 199 225 213 206 207 groups 0 -10 Q3-21 Q4-21 Q1-22 Q2-22 Q3-22 Revenue (DKKm) Gross margin (%)
Slide 7: Hybrid Cloud Solutions (HCS)
Hybrid Cloud Solutions (HCS) • Slight decline in revenue caused Revenue and gross margin mainly by SLA contract expiry in Q1 400 5.9% 4.7% 3.4% 2.5% 10 3.0% 200 0 • Increasing electricity costs and 308 314 290 295 302 higher staff costs during relocation 0 -10 of outsourcing to the Philippines Q3-21
Slide 8: Group financials Q3 and 9M 2022
Group financials Q3 and 9M 2022 Q3-22 BU revenue DKKm Q3-22 Q3-21 9M-22 9M-21 FY-21 Revenue 738 698 2,162 2,139 2,877 Revenue growth 5.7% 6.1% 1.1% 1.3% 1.7% 31% 41% Gross profit 100 90 232 315 420 Sales and marketing costs 35 36 113 109 145 28% Administrative expenses 35 33 109 101 133 Operating pr
Slide 9: 2022 outlook suspended
2022 outlook suspended • IO business to be reclassified as ‘discontinued activities’ • Impact on financial reporting still pending • Temporary suspension maintained • Strengthen revenue and profitability of continuing activities from 2023 9
Slide 10: Closing remarks
Closing remarks Continuation of Growth in revenue, Impact of divestment on carveout work and earnings and backlog in continuing business outsourcing consolidation LSS and CDS still pending 10
Slide 11: Q&A
Q&A NNIT
Slide 12: Contact information
Contact information Pernille Fabricius CFO PNFA@nnit.com 12
Slide 13: We make a mark
We make a mark nnit.com ANIT
Slide 14: Appendix: Life Sciences Solutions
Appendix: Life Sciences Solutions DKKm Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Revenue 229 222 198 199 191 Life Sciences (excl. NGG) 208 201 170 175 166 - Life Sciences (Int.) 202 192 163 167 160 - Life Sciences (DK) 6 9 7 8 6 Novo Nordisk Group 21 21 28 24 24 Public 0 0 0 0 1 Production costs 180 1
Slide 15: Appendix: Cloud & Digital Solutions
Appendix: Cloud & Digital Solutions DKKm Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2022 Revenue 207 206 213 225 199 Life Sciences (excl. NGG) 42 35 35 40 31 - Life Sciences (Int.) 18 12 11 17 12 - Life Sciences (DK) 24 23 24 23 19 Novo Nordisk Group 25 23 23 23 21 Enterprise 100 103 106 111 101 Public 34 3
Slide 16: Appendix: Hybrid Cloud Solutions
Appendix: Hybrid Cloud Solutions DKKm Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2022 Revenue 302 295 290 314 308 Life Sciences (excl. NGG) 36 37 39 45 48 - Life Sciences (Int.) 14 10 14 15 15 - Life Sciences (DK) 22 27 25 30 33 Novo Nordisk Group 97 90 89 107 98 Enterprise 81 86 81 83 81 Public 25 22 24 25